ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A high percentage of patients with Ph+ CML in the chronic phase now experience near-normal life expectancies owing to the availability of BCR-ABL1 tyrosine kinase inhibitors (TKIs).